Pembrolizumab (Pembro) plus lenalidomide (Len) and low-dose dexamethasone (Dex) for relapsed/refractory multiple myeloma (RRMM): Efficacy and biomarker analyses.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.8015
Abstract: 8015Background: The PD-1 inhibitor pembro blocks interaction of PD-1 with its ligands PD-L1/PD-L2, activating antitumor immunity. Combination of pembro, len, and dex may provide synergistic antitum... read more here.
Keywords: lenalidomide len; dex; pembro; plus lenalidomide ... See more keywords
Maintenance therapy (MT) with 25 versus 5 mg lenalidomide (Len) after prolonged Len consolidation therapy (CT) in newly-diagnosed, transplant-eligible patients (pts) with multiple myeloma (MM).
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.8016
Abstract: 8016Background: While Len MT after high-dose therapy (HDT) and autologous blood stem cell transplantation (aBSCT) is standard of care in pts with MM, optimal dosage has not been established. Method... read more here.
Keywords: maintenance therapy; lenalidomide len; len prolonged; therapy versus ... See more keywords